OMER
Omeros Corporation
Biotechnology
Market Cap$1.03B
5Y Perf.-1.6%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
OMER vs HALO vs ACAD vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
HALO
Halozyme Therapeutics, Inc.
Biotechnology
Market Cap$7.68B
5Y Perf.+168.6%
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.86B
5Y Perf.-54.6%
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-61.8%
OMER vs HALO vs ACAD vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | OMER | HALO | ACAD | RARE |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $1.03B | $7.68B | $3.86B | $2.57B |
| Revenue (TTM) | $0.00 | $1.40B | $1.10B | $669M |
| Net Income (TTM) | $-121M | $317M | $376M | $-609M |
| Gross Margin | — | 81.9% | 91.5% | 83.6% |
| Operating Margin | — | 58.4% | 7.4% | -83.9% |
| Forward P/E | — | 8.1x | 50.9x | — |
| Total Debt | $207M | $0.00 | $52M | $1.28B |
| Cash & Equiv. | $3M | $134M | $178M | $434M |
OMER vs HALO vs ACAD vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
OMER
HALO
ACAD
RARE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Omeros Corporation (OMER) | 100 | 98.4 | -1.6% |
| Halozyme Therapeuti… (HALO) | 100 | 268.6 | +168.6% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 45.4 | -54.6% |
| Ultragenyx Pharmace… (RARE) | 100 | 38.2 | -61.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OMER vs HALO vs ACAD vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: HALO leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. ACADIA Pharmaceuticals Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. OMER also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
OMER
Omeros Corporation
The Momentum Pick
OMER is the clearest fit if your priority is momentum.
- +130.6% vs RARE's -21.8%
Best for: momentum
HALO
Halozyme Therapeutics, Inc.
The Income Pick
HALO carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.56
- Rev growth 37.6%, EPS growth -25.4%, 3Y rev CAGR 28.4%
- 5.7% 10Y total return vs OMER's 16.6%
- Lower volatility, beta 0.56, current ratio 4.66x
Best for: income & stability and growth exposure
ACAD
ACADIA Pharmaceuticals Inc.
The Quality Compounder
ACAD is the #2 pick in this set and the best alternative if quality and efficiency is your priority.
- 34.3% margin vs RARE's -91.0%
- 26.2% ROA vs OMER's -53.9%, ROIC 10.0% vs -72.4%
Best for: quality and efficiency
RARE
Ultragenyx Pharmaceutical Inc.
The Growth Angle
RARE lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | HALO | 37.6% revenue growth vs OMER's 11.4% |
| Value | HALO | Better valuation composite |
| Quality / Margins | ACAD | 34.3% margin vs RARE's -91.0% |
| Stability / Safety | HALO | Beta 0.56 vs RARE's 1.42 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | OMER | +130.6% vs RARE's -21.8% |
| Efficiency (ROA) | ACAD | 26.2% ROA vs OMER's -53.9%, ROIC 10.0% vs -72.4% |
OMER vs HALO vs ACAD vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2018
FY 2025
OMER vs HALO vs ACAD vs RARE — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLHALOLAGGINGRARE
Who Leads Where
HALO leads in 3 of 6 categories
OMER leads 1 • ACAD leads 0 • RARE leads 0 • 1 tied
Explore the data ↓RAREUltragenyx Pharmaceut…
0leads
ACADACADIA Pharmaceutical…
0leads
OMEROmeros Corporation
1leads
HALOHalozyme Therapeutics…
3leads
6 Total Categories
CATEGORYLEADERvs OMERvs ACADMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
HALO3/6
Valuation MetricsMultiples, price ratios, and targets
HALO3/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
HALO6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
OMER3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
HALO leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HALO and OMER operate at a comparable scale, with $1.4B and $0 in trailing revenue. ACAD is the more profitable business, keeping 34.3% of every revenue dollar as net income compared to RARE's -91.0%. On growth, HALO holds the edge at +51.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | OMEROmeros Corporation | HALOHalozyme Therapeu… | ACADACADIA Pharmaceut… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $1.4B | $1.1B | $669M |
| EBITDAEarnings before interest/tax | -$127M | $945M | $96M | -$536M |
| Net IncomeAfter-tax profit | -$121M | $317M | $376M | -$609M |
| Free Cash FlowCash after capex | -$105M | $645M | $212M | -$487M |
| Gross MarginGross profit ÷ Revenue | — | +81.9% | +91.5% | +83.6% |
| Operating MarginEBIT ÷ Revenue | — | +58.4% | +7.4% | -83.9% |
| Net MarginNet income ÷ Revenue | — | +22.7% | +34.3% | -91.0% |
| FCF MarginFCF ÷ Revenue | — | +46.2% | +19.4% | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +51.6% | +9.7% | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +16.1% | -2.1% | -81.8% | -17.2% |
HALO leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
HALO leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 9.9x trailing earnings, ACAD trades at a 61% valuation discount to HALO's 25.5x P/E. On an enterprise value basis, HALO's 8.3x EV/EBITDA is more attractive than ACAD's 26.9x.
| Metric | OMEROmeros Corporation | HALOHalozyme Therapeu… | ACADACADIA Pharmaceut… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| Market CapShares × price | $1.0B | $7.7B | $3.9B | $2.6B |
| Enterprise ValueMkt cap + debt − cash | $1.2B | $7.5B | $3.7B | $3.4B |
| Trailing P/EPrice ÷ TTM EPS | -5.42x | 25.46x | 9.85x | -4.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 8.09x | 50.91x | — |
| PEG RatioP/E ÷ EPS growth rate | — | 1.11x | — | — |
| EV / EBITDAEnterprise value multiple | — | 8.34x | 26.91x | — |
| Price / SalesMarket cap ÷ Revenue | — | 5.50x | 3.61x | 3.82x |
| Price / BookPrice ÷ Book value/share | — | 165.47x | 3.15x | — |
| Price / FCFMarket cap ÷ FCF | — | 11.91x | 36.74x | — |
HALO leads this category, winning 3 of 6 comparable metrics.
Profitability & Efficiency
HALO leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
HALO delivers a 6.5% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-6 for RARE. On the Piotroski fundamental quality scale (0–9), ACAD scores 6/9 vs OMER's 3/9, reflecting solid financial health.
| Metric | OMEROmeros Corporation | HALOHalozyme Therapeu… | ACADACADIA Pharmaceut… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | +6.5% | +35.6% | -6.1% |
| ROA (TTM)Return on assets | -53.9% | +12.5% | +26.2% | -45.8% |
| ROICReturn on invested capital | -72.4% | +73.4% | +10.0% | -89.4% |
| ROCEReturn on capital employed | -64.8% | +38.2% | +10.1% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 | 6 | 4 |
| Debt / EquityFinancial leverage | — | — | 0.04x | — |
| Net DebtTotal debt minus cash | $204M | -$134M | -$126M | $842M |
| Cash & Equiv.Liquid assets | $3M | $134M | $178M | $434M |
| Total DebtShort + long-term debt | $207M | $0 | $52M | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | -5.80x | 46.08x | — | -14.49x |
HALO leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
OMER leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HALO five years ago would be worth $13,704 today (with dividends reinvested), compared to $2,281 for RARE. Over the past 12 months, OMER leads with a +130.6% total return vs RARE's -21.8%. The 3-year compound annual growth rate (CAGR) favors OMER at 43.1% vs RARE's -17.8% — a key indicator of consistent wealth creation.
| Metric | OMEROmeros Corporation | HALOHalozyme Therapeu… | ACADACADIA Pharmaceut… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -10.6% | -7.3% | -13.7% | +10.7% |
| 1-Year ReturnPast 12 months | +130.6% | -7.1% | +52.4% | -21.8% |
| 3-Year ReturnCumulative with dividends | +192.8% | +115.3% | +4.7% | -44.5% |
| 5-Year ReturnCumulative with dividends | -17.5% | +37.0% | +7.1% | -77.2% |
| 10-Year ReturnCumulative with dividends | +16.6% | +570.7% | -22.9% | -59.4% |
| CAGR (3Y)Annualised 3-year return | +43.1% | +29.1% | +1.5% | -17.8% |
OMER leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — OMER and HALO each lead in 1 of 2 comparable metrics.
Risk & Volatility
HALO is the less volatile stock with a 0.56 beta — it tends to amplify market swings less than RARE's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. OMER currently trades 82.9% from its 52-week high vs RARE's 61.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OMEROmeros Corporation | HALOHalozyme Therapeu… | ACADACADIA Pharmaceut… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.79x | 0.56x | 1.26x | 1.42x |
| 52-Week HighHighest price in past year | $17.65 | $82.22 | $27.81 | $42.37 |
| 52-Week LowLowest price in past year | $2.95 | $47.50 | $14.45 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +82.9% | +79.3% | +81.1% | +61.7% |
| RSI (14)Momentum oscillator 0–100 | 70.5 | 52.4 | 44.2 | 66.6 |
| Avg Volume (50D)Average daily shares traded | 1.0M | 1.4M | 1.8M | 1.8M |
Evenly matched — OMER and HALO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: OMER as "Buy", HALO as "Buy", ACAD as "Buy", RARE as "Buy". Consensus price targets imply 173.2% upside for OMER (target: $40) vs 20.2% for HALO (target: $78).
| Metric | OMEROmeros Corporation | HALOHalozyme Therapeu… | ACADACADIA Pharmaceut… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $40.00 | $78.33 | $34.78 | $51.50 |
| # AnalystsCovering analysts | 19 | 27 | 37 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.2% | +4.5% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
HALO leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). OMER leads in 1 (Total Returns). 1 tied.
Best OverallHalozyme Therapeutics, Inc. (HALO)Leads 3 of 6 categories
Loading custom metrics...
OMER vs HALO vs ACAD vs RARE: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is OMER or HALO or ACAD or RARE a better buy right now?
For growth investors, Halozyme Therapeutics, Inc.
(HALO) is the stronger pick with 37. 6% revenue growth year-over-year, versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 9x trailing P/E (50. 9x forward), making it the more compelling value choice. Analysts rate Omeros Corporation (OMER) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — OMER or HALO or ACAD or RARE?
On trailing P/E, ACADIA Pharmaceuticals Inc.
(ACAD) is the cheapest at 9. 9x versus Halozyme Therapeutics, Inc. at 25. 5x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 1x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — OMER or HALO or ACAD or RARE?
Over the past 5 years, Halozyme Therapeutics, Inc.
(HALO) delivered a total return of +37. 0%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: HALO returned +570. 7% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — OMER or HALO or ACAD or RARE?
By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.
(HALO) is the lower-risk stock at 0. 56β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 154% more volatile than HALO relative to the S&P 500.
05Which is growing faster — OMER or HALO or ACAD or RARE?
By revenue growth (latest reported year), Halozyme Therapeutics, Inc.
(HALO) is pulling ahead at 37. 6% versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc. grew EPS 68. 4% year-over-year, compared to -43. 6% for Omeros Corporation. Over a 3-year CAGR, HALO leads at 28. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — OMER or HALO or ACAD or RARE?
ACADIA Pharmaceuticals Inc.
(ACAD) is the more profitable company, earning 36. 5% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -79. 5% for RARE. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is OMER or HALO or ACAD or RARE more undervalued right now?
On forward earnings alone, Halozyme Therapeutics, Inc.
(HALO) trades at 8. 1x forward P/E versus 50. 9x for ACADIA Pharmaceuticals Inc. — 42. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OMER: 173. 2% to $40. 00.
08Which pays a better dividend — OMER or HALO or ACAD or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is OMER or HALO or ACAD or RARE better for a retirement portfolio?
For long-horizon retirement investors, Halozyme Therapeutics, Inc.
(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +570. 7% 10Y return). Both have compounded well over 10 years (HALO: +570. 7%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between OMER and HALO and ACAD and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: OMER is a small-cap quality compounder stock; HALO is a small-cap high-growth stock; ACAD is a small-cap deep-value stock; RARE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.